Psoriasis drug Raptiva® pulled from U.S. market

Raptiva® will be pulled from the U.S. market after reports associating the psoriasis drug with the development of progressive multifocal leukoencephalopathy (PML), a rare and serious neurologic disease that affects the central nervous system.